福岡 順也 教授
- May/1995 Japanese Medical License Registration No. 375424
- Sep/1999 Japanese License for Autopsy No. 7186
- Aug/2000 Japanese Board of Pathology No. 2210
- Sep/2004 PhD; Doctor of Pathology (Shiga Univ. of Med Sci)
- Dec/2006 Japanese Board of Cytology No. 2370
- 4. Hashisako M, Fukuoka J. Pathology of Idiopathic Interstitial Pneumonias. Clin Med Insights Circ Respir Pulm Med. 2016: 9(Suppl1):123-33
- 12. Kondoh Y, Johkoh T, Fukuoka J, et al. Broader criteria of undifferentiated connective tissue disease in idiopathic interstitial pneumonias. Respir Med. 2015;109(3):389-396.
- 14. Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. European journal of radiology. 2015;84(3):542-546.
- 24: Tabata K, Fukuoka J.
Histopathologic features of usual interstitial pneumonia and related patterns: what is important for radiologists? Semin Ultrasound CT MR. 2014 Feb;35(1):2-11.
- 25: Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S, Fukuoka J.
Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. BMC Clin Pathol. 2014 May 13; 14-23.
“Do you have a dream?” Having the right dream is a critical part to being a good leader. Hence, I would passionately teach the importance of having one’s own big dream, along with the pathological approach of global medicine. For global health projects, what we focus on right now are 1) education on the diagnostic approach and ways of extracting ideas for research from routine practice to the pathologists from Asian countries, such as Myanmar, Malaysia, and Vietnam, 2) spreading of digital networks for pathology diagnosis and education to the developing countries, and 3) applying our unique tissue array methods to support difficulties of molecular analysis in developing countries. By providing the specific pathological expertise to the local health centers through above projects, I believe we can contribute to treat global patients.